Results for tag: "Gastric Neuroendocrine Tumor Drug"

Gastric Neuroendocrine Tumors (NETs) are a rare type of cancer that originate in the cells of the digestive system. NETs are typically slow-growing and can be difficult to diagnose. Treatment for NETs typically involves a combination of surgery, chemotherapy, and targeted therapies. Oncology drugs used to treat NETs include somatostatin analogs, such as octreotide and lanreotide, which are used to reduce the production of hormones and slow tumor growth. Other drugs used to treat NETs include chemotherapy agents, such as capecitabine and temozolomide, and targeted therapies, such as everolimus and sunitinib. Companies in the Gastric Neuroendocrine Tumor Drug market include Novartis, Pfizer, Merck, and AstraZeneca. Show Less Read more